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Allogeneic hematopoietic stem cell transplantation (HSCT) is a well-established therapy for a 
variety of malignant and non-malignant disorders of the hematopoietic system and for certain 
solid tumors. One of the major complications limiting the success and wider application of 
allogeneic HSCT is the occurrence of acute graft-versus-host disease (GVHD), which is a 
rapidly progressive illness with epithelial damage of gut, liver, skin, and lung, 
immunosuppression and cachexia. GVHD is mediated by alloreactive donor T cells contained in 
the graft and can be prevented by depletion of these T cells prior to transfer. However, 
alloreactive donor T cells also mediate the so-called graft-versus-tumor (GVT) effect, which is 
increasingly being recognized as an important component of the overall anti-tumor effect of an 
allogeneic HSCT. Therefore, a major focus of current research is to ameliorate GVHD without 
reducing GVT activity. Recent murine bone marrow transplantation studies suggest that 
interfering with T cell migration represents an attractive therapeutic approach towards this goal.  
Three families of migration molecules (selectins, chemokines, integrins, and their respective 
ligands and receptors) control T cell migration in homeostasis and inflammation, and members 
of all three families have been identified as important players during GVHD. Recently, 
especially chemokines and chemokine receptors have been evaluated as possible new targets for 
GVHD therapy.  
In the present study, the role of the inflammatory chemokine receptor CCR2 for donor CD8+ T 
cell migration during GVHD was analyzed in well-established murine bone marrow 
transplantation models. It was found that recipients of CCR2-deficient (CCR2-/-) CD8+ T cells 
develop significantly less GVHD morbidity and mortality than recipients of wild type CD8+ T 
cells and that this correlates with reduced target organ damage to the gut and liver. A competitive 
in vivo migration assay revealed that CCR2-/- CD8+ T cells have an intrinsic migratory defect to 
the gut and liver, which was previously unknown. Other causes for the reduction in GVHD could 
be excluded, as alloreactive proliferation, activation, IFN-γ production and in vitro cytotoxicity 
of CCR2-/- CD8+ T cells were intact. Importantly, the GVT effect of CCR2-/- CD8+ T cells 
against murine P815 mastocytoma and A20 B cell lymphoma was preserved, which 
demonstrates that interference with T cell migration by blockade of CCR2 signaling can separate 
GVHD from GVT activity. These data provide first evidence for a critical role of CCR2 for the 
control of CD8+ T cell migration in a pre-clinical disease model and establish the rationale for 
the use of CCR2 antagonists possibly in combination with other chemokine receptor antagonists 
as novel therapeutic tools in GVHD. 
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